| 1 |
Mishra N, Aden K, Blase JI, Baran N, Bordoni D, Tran F, Conrad C, Avalos D, Jaeckel C, Scherer M, Sørensen SB, Overgaard SH, Schulte B, Nikolaus S, Rey G, Gasparoni G, Lyons PA, Schultze JL, Walter J, Andersen V, Banos A, Bertsias G, Beyer M, Boumpas D, Finckh A, Franke A, Georges M, Gu W, Häsler R, Jawhara M, Kenyon A, Kratsch C, Krause R, Lauc G, Mangino M, Natoli G, Ostaszewski M, Pezer M, Raes J, Rahmouni S, Ramos-pamplona M, Reiz B, Rosati E, Sanoudou D, Satagopam V, Schneider R, Schulte-schrepping J, Sidiropoulos P, Smith KGC, Spector T, Vandeputte D, Vieira-silva S, Vojta A, Warnat-herresthal S, Zoldoš V, Dermitzakis ET, Schreiber S, Rosenstiel P; SYSCID Consortium. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med 2022;14. [DOI: 10.1186/s13073-022-01112-z] [Reference Citation Analysis]
|
| 2 |
Yoganathan P, Rossel JB, Jordi SBU, Franc Y, Biedermann L, Misselwitz B, Hausmann M, Rogler G, Scharl M, Frey-Wagner I; Swiss IBD cohort study group. Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterol 2021;21:310. [PMID: 34344313 DOI: 10.1186/s12876-021-01880-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 3 |
Gareb B, Beugeling M, Posthumus S, Otten AT, Dijkstra G, Kosterink JG, Frijlink HW. Infliximab formulation strategy for a stable ileo-colonic targeted oral dosage form intended for the topical treatment of inflammatory bowel disease. Journal of Drug Delivery Science and Technology 2021;64:102552. [DOI: 10.1016/j.jddst.2021.102552] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Yang A, Liu H, Liu F, Fan L, Liao W, Guo J, He K. Study of the Mechanism of the Reyanning Mixture Involved in Treating Novel Coronavirus Pneumonia Based on Network Pharmacology. Natural Product Communications 2020;15:1934578X2095459. [DOI: 10.1177/1934578x20954593] [Reference Citation Analysis]
|
| 5 |
Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
|
| 6 |
Takač B, Mihaljević S, Glavaš-Obrovac L, Kibel A, Suver-Stević M, Canecki-Varžić S, Samardžija M, Rajkovac I, Kovač D, Štefanić M. INTERACTIONS AMONG INTERLEUKIN-6, C-REACTIVE PROTEIN AND INTERLEUKIN-6 (-174) G/C POLYMORPHISM IN THE PATHOGENESIS OF CROHN'S DISEASE AND ULCERATIVE COLITIS. Acta Clin Croat 2020;59:67-80. [PMID: 32724277 DOI: 10.20471/acc.2020.59.01.09] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 7 |
Sun X, Wen K, Xu Z, He Z, Wu B, Yang X, Wang X. Effect of Loureirin B on Crohn's disease rat model induced by TNBS via IL-6/STAT3/NF-κB signaling pathway. Chin Med 2020;15:2. [PMID: 31911815 DOI: 10.1186/s13020-019-0282-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 8 |
Bae JM, Lee HH, Lee BI, Lee KM, Eun SH, Cho ML, Kim JS, Park JM, Cho YS, Lee IS, Kim SW, Choi H, Choi MG. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther 2018;48:196-205. [PMID: 29869804 DOI: 10.1111/apt.14822] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 9 |
Sugita N, Watanabe K, Kamata N, Yukawa T, Otani K, Hosomi S, Nagami Y, Tanaka F, Taira K, Yamagami H, Tanigawa T, Shiba M, Watanabe T, Tominaga K, Kabata D, Shintani A, Arakawa T, Fujiwara Y. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. J Gastroenterol Hepatol 2018;33:631-7. [PMID: 28857255 DOI: 10.1111/jgh.13969] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 10 |
Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. J Crohns Colitis 2017;11:1238-46. [PMID: 28967957 DOI: 10.1093/ecco-jcc/jjx081] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 16.0] [Reference Citation Analysis]
|
| 11 |
Jiang Y, Lin O, Sinha SR. Use of Tumor Necrosis Factor Alpha Inhibitors for Inflammatory Bowel Disease Patients with Concurrent Heart Failure. Dig Dis Sci 2017;62:1597-606. [PMID: 28417241 DOI: 10.1007/s10620-017-4574-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 12 |
Lai Y, Wang R, Chen X, Tang D, Hu Y, Cai J, Zhang Q, Hu H. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016). Hum Vaccin Immunother 2017;13:1-10. [PMID: 28301271 DOI: 10.1080/21645515.2017.1286433] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 13 |
Kanai T. Leukocytapheresis Therapy of Inflammatory Bowel Disease. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_49] [Reference Citation Analysis]
|
| 14 |
Gutiérrez A, Zapater P, Juanola O, Sempere L, García M, Laveda R, Martínez A, Scharl M, González-Navajas JM, Such J, Wiest R, Rogler G, Francés R. Gut Bacterial DNA Translocation is an Independent Risk Factor of Flare at Short Term in Patients With Crohn's Disease. Am J Gastroenterol 2016;111:529-40. [PMID: 26902226 DOI: 10.1038/ajg.2016.8] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 15 |
Broekman MM, Roelofs HM, Hoentjen F, Wiegertjes R, Stoel N, Joosten LA, de Jong DJ, Wanten GJ. LPS-Stimulated Whole Blood Cytokine Production Is Not Related to Disease Behavior in Patients with Quiescent Crohn's Disease. PLoS One 2015;10:e0133932. [PMID: 26208333 DOI: 10.1371/journal.pone.0133932] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 16 |
Alnabhani Z, Montcuquet N, Biaggini K, Dussaillant M, Roy M, Ogier-Denis E, Madi A, Jallane A, Feuilloley M, Hugot JP, Connil N, Barreau F. Pseudomonas fluorescens alters the intestinal barrier function by modulating IL-1β expression through hematopoietic NOD2 signaling. Inflamm Bowel Dis 2015;21:543-55. [PMID: 25659087 DOI: 10.1097/MIB.0000000000000291] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 17 |
Rescigno M. Microbial Sensing and Regulation of Mucosal Immune Responses by Intestinal Epithelial Cells. Mucosal Immunology 2015. [DOI: 10.1016/b978-0-12-415847-4.00028-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 18 |
Joo M, Kim HS, Kwon TH, Palikhe A, Zaw TS, Jeong JH, Sohn UD. Anti-inflammatory Effects of Flavonoids on TNBS-induced Colitis of Rats. Korean J Physiol Pharmacol. 2015;19:43-50. [PMID: 25605996 DOI: 10.4196/kjpp.2015.19.1.43] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 19 |
Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: A desire to treat without drugs. World J Gastroenterol 2014; 20(29): 9699-9715 [PMID: 25110409 DOI: 10.3748/wjg.v20.i29.9699] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 20 |
Dotan I, Mayer L. Intestinal Immunity. Microbial Pathogenesis and the Intestinal Epithelial Cell 2014. [DOI: 10.1128/9781555817848.ch3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 21 |
Weinstock JV. Crohn's Disease. Granulomatous Infections and Inflammations 2014. [DOI: 10.1128/9781555817879.ch11] [Reference Citation Analysis]
|
| 22 |
Yoshino T, Nakase H, Minami N, Yamada S, Matsuura M, Yazumi S, Chiba T. Efficacy and safety of granulocyte and monocyte adsorption apheresis for ulcerative colitis: a meta-analysis. Dig Liver Dis 2014;46:219-26. [PMID: 24268950 DOI: 10.1016/j.dld.2013.10.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 23 |
Laing B, Han DY, Ferguson LR. Candidate genes involved in beneficial or adverse responses to commonly eaten brassica vegetables in a New Zealand Crohn's disease cohort. Nutrients 2013;5:5046-64. [PMID: 24352087 DOI: 10.3390/nu5125046] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 24 |
Fang F, Liu GC, Zhou X, Yang S, Reich HN, Williams V, Hu A, Pan J, Konvalinka A, Oudit GY, Scholey JW, John R. Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. PLoS One 2013;8:e71433. [PMID: 23951161 DOI: 10.1371/journal.pone.0071433] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 25 |
Kruis W, Katalinic A, Klugmann T, Franke GR, Weismüller J, Leifeld L, Ceplis-Kastner S, Reimers B, Bokemeyer B. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohns Colitis 2013;7:e263-70. [PMID: 23182164 DOI: 10.1016/j.crohns.2012.10.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 26 |
Tominaga K, Nakano M, Hoshino M, Kanke K, Hiraishi H. Efficacy, safety and cost analyses in ulcerative colitis patients undergoing granulocyte and monocyte adsorption or receiving prednisolone. BMC Gastroenterol. 2013;13:41. [PMID: 23452668 DOI: 10.1186/1471-230x-13-41] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 27 |
Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012;18:2225-31. [PMID: 22359399 DOI: 10.1002/ibd.22925] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 28 |
Pacheco RG, Esposito CC, Müller LC, Castelo-Branco MT, Quintella LP, Chagas VLA, de Souza HSP, Schanaider A. Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis. World J Gastroenterol 2012; 18(32): 4278-4287 [PMID: 22969190 DOI: 10.3748/wjg.v18.i32.4278] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 41] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 29 |
Steinkamp M, Schulte N, Spaniol U, Pflüger C, Hartmann C, Kirsch J, von Boyen GB. Brain derived neurotrophic factor inhibits apoptosis in enteric glia during gut inflammation. Med Sci Monit 2012;18:BR117-22. [PMID: 22460084 DOI: 10.12659/msm.882612] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 30 |
C Leitner G, Worel N, Vogelsang H. Selective Granulocyte and Monocyte Apheresis as a Non-Pharmacological Option for Patients with Inflammatory Bowel Disease. Transfus Med Hemother 2012;39:246-52. [PMID: 22969694 DOI: 10.1159/000341801] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 31 |
Zorzi F, Zuzzi S, Onali S, Calabrese E, Condino G, Petruzziello C, Ascolani M, Pallone F, Biancone L. Efficacy and safety of infliximab and adalimumab in Crohn's disease: a single centre study. Aliment Pharmacol Ther 2012;35:1397-407. [PMID: 22519466 DOI: 10.1111/j.1365-2036.2012.05100.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
|
| 32 |
Wan YM, Zhu YQ, Yang JH, You LY, Yang J, Luo J. Therapeutic effect of a probiotic compound on TNBS-induced colitis in rats. Shijie Huaren Xiaohua Zazhi 2012; 20(1): 66-69 [DOI: 10.11569/wcjd.v20.i1.66] [Reference Citation Analysis]
|
| 33 |
Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol 2012;30:149-73. [PMID: 22224779 DOI: 10.1146/annurev-immunol-020711-075001] [Cited by in Crossref: 276] [Cited by in F6Publishing: 319] [Article Influence: 25.1] [Reference Citation Analysis]
|
| 34 |
Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol 2011;4:375-89. [PMID: 22043230 DOI: 10.1177/1756283X11413315] [Cited by in Crossref: 40] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 35 |
Ando T, Watanabe O, Nishio Y, Ishiguro K, Maeda O, Nakamura M, Miyahara R, Ohmiya N, Goto H. Novel Techniques in Endoscopy Are Useful in Evaluating Patients with Ulcerative Colitis. Ulcers 2011;2011:1-6. [DOI: 10.1155/2011/398785] [Reference Citation Analysis]
|
| 36 |
Borowiec AM, Fedorak RN. Predicting, treating and preventing postoperative recurrence of Crohn's disease: the state of the field. Can J Gastroenterol. 2011;25:140-146. [PMID: 21499578 DOI: 10.1155/2011/591347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 37 |
Feagan BG, Hanauer SB, Coteur G, Schreiber S. Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther 2011;33:1143-51. [PMID: 21443536 DOI: 10.1111/j.1365-2036.2011.04636.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 38 |
Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011;106:685-98. [PMID: 21427713 DOI: 10.1038/ajg.2011.103] [Cited by in Crossref: 233] [Cited by in F6Publishing: 227] [Article Influence: 19.4] [Reference Citation Analysis]
|
| 39 |
Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-recognition receptors in Crohn's disease. Nat Rev Gastroenterol Hepatol 2011;8:152-68. [PMID: 21304476 DOI: 10.1038/nrgastro.2011.3] [Cited by in Crossref: 111] [Cited by in F6Publishing: 114] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 40 |
Feagan BG, Sandborn WJ, Wolf DC, Coteur G, Purcaru O, Brabant Y, Rutgeerts PJ. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment Pharmacol Ther 2011;33:541-50. [PMID: 21223344 DOI: 10.1111/j.1365-2036.2010.04568.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 41 |
von Boyen GB, Schulte N, Pflüger C, Spaniol U, Hartmann C, Steinkamp M. Distribution of enteric glia and GDNF during gut inflammation. BMC Gastroenterol. 2011;11:3. [PMID: 21235736 DOI: 10.1186/1471-230x-11-3] [Cited by in Crossref: 93] [Cited by in F6Publishing: 102] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 42 |
Vos AC, Wildenberg ME, Duijvestein M, Verhaar AP, van den Brink GR, Hommes DW. Anti-tumor necrosis factor-α antibodies induce regulatory macrophages in an Fc region-dependent manner. Gastroenterology 2011;140:221-30. [PMID: 20955706 DOI: 10.1053/j.gastro.2010.10.008] [Cited by in Crossref: 151] [Cited by in F6Publishing: 154] [Article Influence: 12.6] [Reference Citation Analysis]
|
| 43 |
Filipenko NV. NONINVASIVE DIAGNOSIS OF ULCERATIVE COLITIS ON THE BASIS OF FECAL LACTOFERRIN AND IMMUNOCHEMICAL HEMOCCULT TEST. jour 2010. [DOI: 10.51523/2708-6011.2010-7-4-30] [Reference Citation Analysis]
|
| 44 |
Rintamäki H, Sipponen T, Salo HM, Vaarala O, Kolho KL. Serum immune-activation potency and response to anti-TNF-α therapy in Crohn's disease. World J Gastroenterol 2010; 16(46): 5845-5851 [PMID: 21155006 DOI: 10.3748/wjg.v16.i46.5845] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 45 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol. 2011;163:50-58. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 46 |
Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg R. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011;163:50-8. [PMID: 21078086 DOI: 10.1111/j.1365-2249.2010.04279.x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 47 |
Yamada A, Sono K, Hosoe N, Takada N, Suzuki Y. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF. Inflamm Bowel Dis 2010;16:1898-904. [PMID: 20310016 DOI: 10.1002/ibd.21259] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 48 |
Kosovac K, Brenmoehl J, Holler E, Falk W, Schoelmerich J, Hausmann M, Rogler G. Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm Bowel Dis 2010;16:1311-21. [PMID: 20232407 DOI: 10.1002/ibd.21223] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 49 |
Hanauer SB, Panes J, Colombel JF, Bloomfield R, Schreiber S, Sandborn WJ. Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn's disease. Aliment Pharmacol Ther 2010;32:384-93. [PMID: 20491747 DOI: 10.1111/j.1365-2036.2010.04360.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 50 |
Lindberg A, Eberhardson M, Karlsson M, Karlén P. Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterol. 2010;10:73. [PMID: 20604939 DOI: 10.1186/1471-230x-10-73] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 51 |
Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ; Precise 3 Study Investigators. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010;8:600-9. [PMID: 20117244 DOI: 10.1016/j.cgh.2010.01.014] [Cited by in Crossref: 80] [Cited by in F6Publishing: 86] [Article Influence: 6.2] [Reference Citation Analysis]
|
| 52 |
Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ; PRECiSE 2 Study Investigators. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol 2010;105:1574-82. [PMID: 20234346 DOI: 10.1038/ajg.2010.78] [Cited by in Crossref: 169] [Cited by in F6Publishing: 155] [Article Influence: 13.0] [Reference Citation Analysis]
|
| 53 |
Engel MA, Neurath MF. New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-83. [PMID: 20213337 DOI: 10.1007/s00535-010-0219-3] [Cited by in Crossref: 130] [Cited by in F6Publishing: 143] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 54 |
Keshaw H, Foong KS, Forbes A, Day RM. Perianal fistulae in Crohn's Disease: current and future approaches to treatment. Inflamm Bowel Dis 2010;16:870-80. [PMID: 19834976 DOI: 10.1002/ibd.21137] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 55 |
Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009;104:2990-5. [PMID: 19724269 DOI: 10.1038/ajg.2009.453] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 56 |
Helmy A, Abdulla M, Kagevi I, Al Kahtani K. Leukocyte apheresis in the management of ulcerative colitis. Saudi J Gastroenterol 2009;15:283-7. [PMID: 19794281 DOI: 10.4103/1319-3767.56093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 57 |
Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009;41:570-7. [PMID: 19211314 DOI: 10.1016/j.dld.2008.11.020] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 58 |
Chowdhury M, Kudara N, Chiba T, Endo M, Akasaka R, Tomita K, Fujiwara S, Mizutani T, Sugai T, Takikawa Y, Suzuki K. Evaluation of Infliximab Effects on Gastrointestinal Bleeding in Crohn's Disease Using Double-Balloon Endoscopy. Case Rep Gastroenterol 2009;3:193-7. [PMID: 21103274 DOI: 10.1159/000224712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 59 |
du Souich P, García AG, Vergés J, Montell E. Immunomodulatory and anti-inflammatory effects of chondroitin sulphate. J Cell Mol Med 2009;13:1451-63. [PMID: 19522843 DOI: 10.1111/j.1582-4934.2009.00826.x] [Cited by in Crossref: 112] [Cited by in F6Publishing: 120] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 60 |
Belmiro CL, Castelo-Branco MT, Melim LM, Schanaider A, Elia C, Madi K, Pavão MS, de Souza HS. Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem 2009;284:11267-78. [PMID: 19258310 DOI: 10.1074/jbc.M807211200] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 61 |
Guzy C, Schirbel A, Paclik D, Wiedenmann B, Dignass A, Sturm A. Enteral and parenteral nutrition distinctively modulate intestinal permeability and T cell function in vitro. Eur J Nutr 2009;48:12-21. [PMID: 18998044 DOI: 10.1007/s00394-008-0754-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 62 |
Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov VI, Stanton D, Graffner H. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment Pharmacol Ther 2008;28:758-67. [PMID: 19145731 DOI: 10.1111/j.1365-2036.2008.03778.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 63 |
D'Incà R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol 2008;103:2007-14. [PMID: 18802997 DOI: 10.1111/j.1572-0241.2008.01870.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 140] [Article Influence: 9.3] [Reference Citation Analysis]
|
| 64 |
Paclik D, Danese S, Berndt U, Wiedenmann B, Dignass A, Sturm A. Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One. 2008;3:e2629. [PMID: 18612433 DOI: 10.1371/journal.pone.0002629] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 65 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Kageoka M, Ikeya K, Yamada M, Kikuyama M, Iwaoka Y, Hirayama K, Nagata S, Sato Y, Hosoda Y. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis 2008;40:433-40. [PMID: 18296130 DOI: 10.1016/j.dld.2008.01.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 66 |
Loganayagam A, Bjarnason I. Stool tests: are they useful? Falk Symposium. [DOI: 10.1007/978-1-4020-6987-1_14] [Reference Citation Analysis]
|
| 67 |
Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Am J Gastroenterol 2008;103:1210-6. [PMID: 18177452 DOI: 10.1111/j.1572-0241.2007.01714.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 82] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 68 |
Yamamoto T, Maruyama Y, Umegae S, Matsumoto K, Saniabadi AR. Mucosal inflammation in the terminal ileum of ulcerative colitis patients: endoscopic findings and cytokine profiles. Dig Liver Dis 2008;40:253-9. [PMID: 18243079 DOI: 10.1016/j.dld.2007.11.020] [Cited by in Crossref: 26] [Cited by in F6Publishing: 53] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 69 |
Panés J, Gomollón F, Taxonera C, Hinojosa J, Clofent J, Nos P. Crohn's disease: a review of current treatment with a focus on biologics. Drugs 2007;67:2511-37. [PMID: 18034589 DOI: 10.2165/00003495-200767170-00005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 70 |
Bruns T, Schmidt C, Stallmach A. Biologicals for treatment of patients with inflammatory bowel diseases — quite in fashion or really necessary? Future Perspectives in Gastroenterology 2008. [DOI: 10.1007/978-1-4020-8833-9_4] [Reference Citation Analysis]
|
| 71 |
Kühbacher T, Schreiber S. Approach to the Patient with Inflammatory Bowel Disease. Capsule Endoscopy 2008. [DOI: 10.1016/b978-1-4160-3402-5.50015-0] [Reference Citation Analysis]
|
| 72 |
Kelly DG. Nutrition in Inflammatory Bowel Disease. Clinical Gastroenterology. [DOI: 10.1007/978-1-59745-320-2_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 73 |
Rogler G. Indications for use of infliximab in inflammatory bowel disease. Falk Symposium. [DOI: 10.1007/978-1-4020-6116-5_18] [Reference Citation Analysis]
|
| 74 |
Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology 2007;133:1670-89. [PMID: 17983810 DOI: 10.1053/j.gastro.2007.09.001] [Cited by in Crossref: 282] [Cited by in F6Publishing: 292] [Article Influence: 17.6] [Reference Citation Analysis]
|
| 75 |
Ren J, Tao Q, Wang X, Wang Z, Li J. Efficacy of T2 in active Crohn's disease: a prospective study report. Dig Dis Sci 2007;52:1790-7. [PMID: 17410440 DOI: 10.1007/s10620-007-9747-y] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 76 |
Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007;39:626-33. [PMID: 17532273 DOI: 10.1016/j.dld.2007.04.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 77 |
Spoettl T, Hausmann M, Klebl F, Dirmeier A, Klump B, Hoffmann J, Herfarth H, Timmer A, Rogler G. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis 2007;13:727-32. [PMID: 17260368 DOI: 10.1002/ibd.20107] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 78 |
Byeon JS, Choi EK, Heo NY, Hong SC, Myung SJ, Yang SK, Kim JH, Song JK, Yoo B, Yu CS. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case. Dis Colon Rectum 2007;50:672-6. [PMID: 17216141 DOI: 10.1007/s10350-006-0813-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 79 |
Lahat G, Halperin D, Barazovsky E, Shalit I, Rabau M, Klausner J, Fabian I. Immunomodulatory effects of ciprofloxacin in TNBS-induced colitis in mice. Inflamm Bowel Dis 2007;13:557-65. [PMID: 17253612 DOI: 10.1002/ibd.20077] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 80 |
Carvalho AT, Souza H, Carneiro AJ, Castelo-Branco M, Madi K, Schanaider A, Silva F, Pereira Jứnior FA, Pereira MG, Tortori C, Dines I, Carvalho J, Rocha E, Elia C. Therapeutic and prophylactic thalidomide in TNBS-induced colitis: Synergistic effects on TNF-α, IL-12 and VEGF production. World J Gastroenterol 2007; 13(15): 2166-2173 [PMID: 17465495 DOI: 10.3748/wjg.v13.i15.2166] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 81 |
Ljung T, Axelsson LG, Herulf M, Lundberg JO, Hellström PM. Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. Aliment Pharmacol Ther 2007;25:925-32. [PMID: 17402996 DOI: 10.1111/j.1365-2036.2007.03284.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 82 |
Takano T, Hohdatsu T, Toda A, Tanabe M, Koyama H. TNF-alpha, produced by feline infectious peritonitis virus (FIPV)-infected macrophages, upregulates expression of type II FIPV receptor feline aminopeptidase N in feline macrophages. Virology 2007;364:64-72. [PMID: 17382365 DOI: 10.1016/j.virol.2007.02.006] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 83 |
Houdeau E, Moriez R, Leveque M, Salvador-Cartier C, Waget A, Leng L, Bueno L, Bucala R, Fioramonti J. Sex steroid regulation of macrophage migration inhibitory factor in normal and inflamed colon in the female rat. Gastroenterology 2007;132:982-93. [PMID: 17324399 DOI: 10.1053/j.gastro.2006.12.028] [Cited by in Crossref: 64] [Cited by in F6Publishing: 68] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 84 |
Reguiaï Z, Grange F. The role of anti-tumor necrosis factor-alpha therapy in Pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol 2007;8:67-77. [PMID: 17428111 DOI: 10.2165/00128071-200708020-00002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 85 |
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577 [PMID: 17171783 DOI: 10.3748/wjg.v12.i47.7568] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 38] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 86 |
Nishio Y, Ando T, Maeda O, Ishiguro K, Watanabe O, Ohmiya N, Niwa Y, Kusugami K, Goto H. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006;55:1768-73. [PMID: 16682428 DOI: 10.1136/gut.2005.086900] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 87 |
Yamamoto T, Saniabadi AR, Umegae S, Matsumoto K. Impact of selective leukocytapheresis on mucosal inflammation and ulcerative colitis: cytokine profiles and endoscopic findings. Inflamm Bowel Dis 2006;12:719-26. [PMID: 16917227 DOI: 10.1097/00054725-200608000-00008] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 88 |
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lémann M, Mary JY; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis 2006;12:551-7. [PMID: 16804391 DOI: 10.1097/01.ibd.0000225334.60990.5b] [Cited by in Crossref: 75] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 89 |
Ljung T, Lundberg S, Varsanyi M, Johansson C, Schmidt PT, Herulf M, Lundberg JO, Hellström PM. Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders versus nonresponders. World J Gastroenterol 2006; 12(21): 3386-3392 [PMID: 16733856 DOI: 10.3748/wjg.v12.i21.3386] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
|
| 90 |
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53. [PMID: 16682258 DOI: 10.1016/j.cgh.2006.03.010] [Cited by in Crossref: 313] [Cited by in F6Publishing: 324] [Article Influence: 18.4] [Reference Citation Analysis]
|
| 91 |
von Boyen GB, Steinkamp M, Geerling I, Reinshagen M, Schäfer KH, Adler G, Kirsch J. Proinflammatory cytokines induce neurotrophic factor expression in enteric glia: a key to the regulation of epithelial apoptosis in Crohn's disease. Inflamm Bowel Dis 2006;12:346-54. [PMID: 16670534 DOI: 10.1097/01.MIB.0000219350.72483.44] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 92 |
Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, Gasche C, Tilg H, Schreiber SW, Schölmerich J, Reinisch W; European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 Suppl 1:i1-15. [PMID: 16481628 DOI: 10.1136/gut.2005.081950a] [Cited by in Crossref: 388] [Cited by in F6Publishing: 449] [Article Influence: 22.8] [Reference Citation Analysis]
|
| 93 |
Schreiber S. Slipping the barrier: how variants in CARD15 could alter permeability of the intestinal wall and population health. Gut 2006;55:308-9. [PMID: 16474103 DOI: 10.1136/gut.2005.076075] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 94 |
Schreiber S, Feagan B, D'Haens G, Colombel JF, Geboes K, Yurcov M, Isakov V, Golovenko O, Bernstein CN, Ludwig D, Winter T, Meier U, Yong C, Steffgen J; BIRB 796 Study Group. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4:325-34. [PMID: 16527696 DOI: 10.1016/j.cgh.2005.11.013] [Cited by in Crossref: 140] [Cited by in F6Publishing: 145] [Article Influence: 8.2] [Reference Citation Analysis]
|
| 95 |
Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-42; quiz 464. [PMID: 16500392 DOI: 10.1016/j.gie.2005.08.011] [Cited by in Crossref: 409] [Cited by in F6Publishing: 426] [Article Influence: 24.1] [Reference Citation Analysis]
|
| 96 |
Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. The impact of the fecal stream and stasis on immunologic reactions in ileal pouch after restorative proctocolectomy for ulcerative colitis: a prospective, pilot study. Am J Gastroenterol 2005;100:2248-53. [PMID: 16181377 DOI: 10.1111/j.1572-0241.2005.50617.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 97 |
Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A; CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18. [PMID: 16143120 DOI: 10.1053/j.gastro.2005.06.064] [Cited by in Crossref: 441] [Cited by in F6Publishing: 454] [Article Influence: 24.5] [Reference Citation Analysis]
|
| 98 |
Pender SL, Chance V, Whiting CV, Buckley M, Edwards M, Pettipher R, MacDonald TT. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model. Gut 2005;54:1114-20. [PMID: 16009684 DOI: 10.1136/gut.2004.052779] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 99 |
Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, García-Gómez M, Leceta J, Gomariz RP. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm Bowel Dis 2005;11:674-84. [PMID: 15973123 DOI: 10.1097/01.mib.0000171872.70738.58] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 100 |
Lichtenstein GR. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy. Am J Gastroenterol 2005;100:1433-5. [PMID: 15984959 DOI: 10.1111/j.1572-0241.2005.50622_1.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 101 |
Reimund JM, Arondel Y, Escalin G, Finck G, Baumann R, Duclos B. Immune activation and nutritional status in adult Crohn's disease patients. Dig Liver Dis 2005;37:424-31. [PMID: 15893281 DOI: 10.1016/j.dld.2005.01.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 102 |
Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis 2005;11:589-96. [PMID: 15905707 DOI: 10.1097/01.mib.0000161917.97136.e2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.2] [Reference Citation Analysis]
|
| 103 |
Vespasiani Gentilucci U, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, Petitti T, Afeltra A, Cicala M. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment Pharmacol Ther 2005;21:1063-71. [PMID: 15854167 DOI: 10.1111/j.1365-2036.2005.02449.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 104 |
Pardi DS, Sandborn WJ. Predicting relapse in patients with inflammatory bowel disease: what is the role of biomarkers? Gut 2005;54:321-2. [PMID: 15710974 DOI: 10.1136/gut.2004.048850] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 105 |
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005;21:373-84. [PMID: 15709987 DOI: 10.1111/j.1365-2036.2005.02336.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 106 |
Homann N, Klarmann U, Fellermann K, Brüning A, Klingenberg-Noftz R, Witthöft T, Stange EF, Ludwig D. Mesenteric pulsatility index analysis predicts response to azathioprine in patients with Crohn's disease. Inflamm Bowel Dis 2005;11:126-32. [PMID: 15677905 DOI: 10.1097/00054725-200502000-00005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 107 |
Konrad A, Mähler M, Arni S, Flogerzi B, Klingelhöfer S, Seibold F. Ameliorative effect of IDS 30, a stinging nettle leaf extract, on chronic colitis. Int J Colorectal Dis 2005;20:9-17. [PMID: 15338166 DOI: 10.1007/s00384-004-0619-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 108 |
Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, Davies MJ, Johnson DA, Turner MJ, Whitehead WE. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004;49:1236-43. [PMID: 15387352 DOI: 10.1023/b:ddas.0000037818.64577.ef] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 109 |
Hanai H, Watanabe F, Yamada M, Sato Y, Takeuchi K, Iida T, Tozawa K, Tanaka T, Maruyama Y, Matsushita I, Iwaoka Y, Saniabadi A. Correlation of serum soluble TNF-alpha receptors I and II levels with disease activity in patients with ulcerative colitis. Am J Gastroenterol 2004;99:1532-8. [PMID: 15307873 DOI: 10.1111/j.1572-0241.2004.30432.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 110 |
Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. [PMID: 15224278 DOI: 10.1016/s1542-3565(04)00238-1] [Cited by in Crossref: 449] [Cited by in F6Publishing: 462] [Article Influence: 23.6] [Reference Citation Analysis]
|
| 111 |
Stallmach A, Giese T, Schmidt C, Ludwig B, Mueller-Molaian I, Meuer SC. Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease. Int J Colorectal Dis 2004;19:308-15. [PMID: 14605835 DOI: 10.1007/s00384-003-0554-4] [Cited by in Crossref: 83] [Cited by in F6Publishing: 88] [Article Influence: 4.4] [Reference Citation Analysis]
|
| 112 |
Trebble TM, Wootton SA, Stroud MA, Mullee MA, Calder PC, Fine DR, Moniz C, Arden NK. Laboratory markers predict bone loss in Crohn's disease: relationship to blood mononuclear cell function and nutritional status. Aliment Pharmacol Ther 2004;19:1063-71. [PMID: 15142195 DOI: 10.1111/j.1365-2036.2004.01943.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 113 |
Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Mucosal cytokine production during remission after resection for Crohn's disease and its relationship to future relapse. Aliment Pharmacol Ther 2004;19:671-8. [PMID: 15023169 DOI: 10.1111/j.1365-2036.2004.01899.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 114 |
Kirkegaard T, Pedersen G, Saermark T, Brynskov J. Tumour necrosis factor-alpha converting enzyme (TACE) activity in human colonic epithelial cells. Clin Exp Immunol 2004;135:146-53. [PMID: 14678276 DOI: 10.1111/j.1365-2249.2004.02348.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 115 |
Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Hanauer SB. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402-13. [PMID: 14762776 DOI: 10.1053/j.gastro.2003.11.014] [Cited by in Crossref: 700] [Cited by in F6Publishing: 722] [Article Influence: 36.8] [Reference Citation Analysis]
|
| 116 |
Waetzig GH, Schreiber S. Mechanisms of infliximab: the reverse side of a drug effect. Inflamm Bowel Dis 2004;10 Suppl 1:S38-43. [PMID: 15168830 DOI: 10.1097/00054725-200402001-00009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 117 |
von Boyen GB, Steinkamp M, Reinshagen M, Schäfer KH, Adler G, Kirsch J. Proinflammatory cytokines increase glial fibrillary acidic protein expression in enteric glia. Gut 2004;53:222-8. [PMID: 14724154 DOI: 10.1136/gut.2003.012625] [Cited by in Crossref: 153] [Cited by in F6Publishing: 163] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 118 |
Kobayashi D, Saito K, Komatsu M, Watanabe N. Clinical Application Of A Highly Sensitive Immuno-Polymerase Chain Reaction For Serum Tumor Necrosis Factor α. Advances in Critical Care Testing 2004. [DOI: 10.1007/978-3-642-18480-2_18] [Reference Citation Analysis]
|
| 119 |
Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br J Clin Pharmacol 2003;56:351-61. [PMID: 12968979 DOI: 10.1046/j.1365-2125.2003.01965.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 120 |
Zimmermann-Nielsen E, Agnholt J, Thorlacius-Ussing O, Dahlerup JF, Baatrup G. Complement activation in plasma before and after infliximab treatment in Crohn disease. Scand J Gastroenterol 2003;38:1050-4. [PMID: 14621279 DOI: 10.1080/00365520310005767] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 121 |
Trebble TM, Wootton SA, May A, Erlewyn-Lajeunesse MD, Chakraborty A, Mullee MA, Stroud MA, Beattie RM. Essential fatty acid status in paediatric Crohn's disease: relationship with disease activity and nutritional status. Aliment Pharmacol Ther 2003;18:433-42. [PMID: 12940929 DOI: 10.1046/j.1365-2036.2003.01707.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 122 |
Wild GE, Waschke KA, Bitton A, Thomson AB. The mechanisms of prednisone inhibition of inflammation in Crohn's disease involve changes in intestinal permeability, mucosal TNFalpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther 2003;18:309-17. [PMID: 12895215 DOI: 10.1046/j.1365-2036.2003.01611.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 123 |
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F. Review article: maintenance treatment of Crohn's disease. Aliment Pharmacol Ther 2003;17 Suppl 2:31-7. [PMID: 12786610 DOI: 10.1046/j.1365-2036.17.s2.20.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 124 |
Rosenstiel P, Fantini M, Bräutigam K, Kühbacher T, Waetzig GH, Seegert D, Schreiber S. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-9. [PMID: 12671897 DOI: 10.1053/gast.2003.50157] [Cited by in Crossref: 313] [Cited by in F6Publishing: 321] [Article Influence: 15.7] [Reference Citation Analysis]
|
| 125 |
Annovazzi A, Biancone L, Caviglia R, Chianelli M, Capriotti G, Mather SJ, Caprilli R, Pallone F, Scopinaro F, Signore A. 99mTc-interleukin-2 and (99m)Tc-HMPAO granulocyte scintigraphy in patients with inactive Crohn's disease. Eur J Nucl Med Mol Imaging 2003;30:374-82. [PMID: 12634965 DOI: 10.1007/s00259-002-1069-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 126 |
Biancone L, Fantini M, Tosti C, Bozzi R, Vavassori P, Pallone F. Fecal alpha 1-antitrypsin clearance as a marker of clinical relapse in patients with Crohn's disease of the distal ileum. Eur J Gastroenterol Hepatol 2003;15:261-6. [PMID: 12610321 DOI: 10.1097/00042737-200303000-00009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 127 |
Agnholt J, Dahlerup JF, Buntzen S, Tøttrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment Pharmacol Ther 2003;17:703-10. [PMID: 12641520 DOI: 10.1046/j.1365-2036.2003.01487.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 128 |
Evans SM, Ashwood P, Warley A, Berisha F, Thompson RP, Powell JJ. The role of dietary microparticles and calcium in apoptosis and interleukin-1beta release of intestinal macrophages. Gastroenterology 2002;123:1543-53. [PMID: 12404229 DOI: 10.1053/gast.2002.36554] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 129 |
Schreiber S, Rosenstiel P, Hampe J, Nikolaus S, Groessner B, Schottelius A, Kühbacher T, Hämling J, Fölsch UR, Seegert D. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease. Gut 2002;51:379-85. [PMID: 12171960 DOI: 10.1136/gut.51.3.379] [Cited by in Crossref: 154] [Cited by in F6Publishing: 158] [Article Influence: 7.3] [Reference Citation Analysis]
|
| 130 |
Simmons J, Jewell DP. Infliximab for ulcerative colitis. Dig Liver Dis 2002;34:616-8. [PMID: 12405245 DOI: 10.1016/s1590-8658(02)80201-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
|
| 131 |
Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34:626-30. [PMID: 12405248 DOI: 10.1016/s1590-8658(02)80204-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 132 |
Hollander D. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg? Am J Gastroenterol 2002;97:1867-8. [PMID: 12190145 DOI: 10.1111/j.1572-0241.2002.05895.x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
|
| 133 |
Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A, Pallone F. Review article: monitoring the activity of Crohn's disease. Aliment Pharmacol Ther 2002;16 Suppl 4:29-33. [PMID: 12047257 DOI: 10.1046/j.1365-2036.16.s4.18.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 134 |
Brynskov J, Foegh P, Pedersen G, Ellervik C, Kirkegaard T, Bingham A, Saermark T. Tumour necrosis factor alpha converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002;51:37-43. [PMID: 12077089 DOI: 10.1136/gut.51.1.37] [Cited by in Crossref: 143] [Cited by in F6Publishing: 155] [Article Influence: 6.8] [Reference Citation Analysis]
|
| 135 |
Arnott ID, Williams N, Drummond HE, Ghosh S. Whole gut lavage fluid interleukin-1beta and interleukin-8 in smokers and non-smokers with Crohn's disease in clinical remission. Dig Liver Dis 2002;34:424-9. [PMID: 12132790 DOI: 10.1016/s1590-8658(02)80040-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 136 |
Arnott ID, Watts D, Ghosh S. Review article: is clinical remission the optimum therapeutic goal in the treatment of Crohn's disease? Aliment Pharmacol Ther 2002;16:857-67. [PMID: 11966492 DOI: 10.1046/j.1365-2036.2002.01242.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 137 |
Jensen-Jarolim E, Gscheidlinger R, Oberhuber G, Neuchrist C, Lucas T, Bises G, Radauer C, Willheim M, Scheiner O, Liu FT, Boltz-Nitulescu G. The constitutive expression of galectin-3 is downregulated in the intestinal epithelia of Crohn's disease patients, and tumour necrosis factor alpha decreases the level of galectin-3-specific mRNA in HCT-8 cells. Eur J Gastroenterol Hepatol 2002;14:145-52. [PMID: 11981338 DOI: 10.1097/00042737-200202000-00008] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 138 |
Meresse B, Rutgeerts P, Malchow H, Dubucquoi S, Dessaint JP, Cohard M, Colombel JF, Desreumaux P. Low ileal interleukin 10 concentrations are predictive of endoscopic recurrence in patients with Crohn's disease. Gut 2002;50:25-8. [PMID: 11772962 DOI: 10.1136/gut.50.1.25] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 1.8] [Reference Citation Analysis]
|
| 139 |
Ten Hove T, Corbaz A, Amitai H, Aloni S, Belzer I, Graber P, Drillenburg P, van Deventer SJ, Chvatchko Y, Te Velde AA. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. Gastroenterology 2001;121:1372-9. [PMID: 11729116 DOI: 10.1053/gast.2001.29579] [Cited by in Crossref: 144] [Cited by in F6Publishing: 156] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 140 |
Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121:1428-36. [PMID: 11729122 DOI: 10.1053/gast.2001.29568] [Cited by in Crossref: 159] [Cited by in F6Publishing: 164] [Article Influence: 7.2] [Reference Citation Analysis]
|
| 141 |
Jensen-Jarolim E, Neumann C, Oberhuber G, Gscheidlinger R, Neuchrist C, Reinisch W, Zuberi RI, Penner E, Liu FT, Boltz-Nitulescu G. Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries. J Clin Immunol 2001;21:348-56. [PMID: 11720007 DOI: 10.1023/a:1012240719801] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 142 |
Tibble J, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7(4): 460-465 [PMID: 11819811 DOI: 10.3748/wjg.v7.i4.460] [Cited by in CrossRef: 115] [Cited by in F6Publishing: 119] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 143 |
Arnott ID, Drummond HE, Ghosh S. Gut mucosal secretion of interleukin 1beta and interleukin-8 predicts relapse in clinically inactive Crohn's disease. Dig Dis Sci 2001;46:402-9. [PMID: 11281191 DOI: 10.1023/a:1005617302718] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 144 |
Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 2001;120:622-35. [PMID: 11179240 DOI: 10.1053/gast.2001.22122] [Cited by in Crossref: 252] [Cited by in F6Publishing: 266] [Article Influence: 11.5] [Reference Citation Analysis]
|
| 145 |
Schreiber S. Immunopathophysiology of inflammatory bowel disease. Immunological Aspects of Gastroenterology 2001. [DOI: 10.1007/978-94-010-0790-0_9] [Reference Citation Analysis]
|
| 146 |
Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000;35:1163-9. [PMID: 11145287 DOI: 10.1080/003655200750056637] [Cited by in Crossref: 122] [Cited by in F6Publishing: 130] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 147 |
Segain JP, Raingeard de la Blétière D, Bourreille A, Leray V, Gervois N, Rosales C, Ferrier L, Bonnet C, Blottière HM, Galmiche JP. Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut 2000;47:397-403. [PMID: 10940278 DOI: 10.1136/gut.47.3.397] [Cited by in Crossref: 886] [Cited by in F6Publishing: 914] [Article Influence: 38.5] [Reference Citation Analysis]
|
| 148 |
Levine AD, Fiocchi C. Immunology of inflammatory bowel disease. Curr Opin Gastroenterol 2000;16:306-9. [PMID: 17031093 DOI: 10.1097/00001574-200007000-00003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 149 |
Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 2000;119:15-22. [PMID: 10889150 DOI: 10.1053/gast.2000.8523] [Cited by in Crossref: 545] [Cited by in F6Publishing: 569] [Article Influence: 23.7] [Reference Citation Analysis]
|
| 150 |
Carty E, De Brabander M, Feakins RM, Rampton DS. Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000;46:487-92. [PMID: 10716677 DOI: 10.1136/gut.46.4.487] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 151 |
Hampe J, Shaw SH, Saiz R, Leysens N, Lantermann A, Mascheretti S, Lynch NJ, MacPherson AJ, Bridger S, van Deventer S, Stokkers P, Morin P, Mirza MM, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME, Schreiber S. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999;65:1647-55. [PMID: 10577918 DOI: 10.1086/302677] [Cited by in Crossref: 154] [Cited by in F6Publishing: 172] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 152 |
Desreumaux P, Nutten S, Colombel JF. Activated eosinophils in inflammatory bowel disease: do they matter? Am J Gastroenterol 1999;94:3396-8. [PMID: 10606287 DOI: 10.1111/j.1572-0241.1999.01657.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 153 |
Reinisch W, Gasché C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, Dejaco C, Waldhör T, Bakos S, Vogelsang H, Gangl A, Lochs H. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999;94:2156-64. [PMID: 10445543 DOI: 10.1111/j.1572-0241.1999.01288.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 131] [Article Influence: 4.3] [Reference Citation Analysis]
|
